- Business Wire•3 days ago
Today, the CEO of Avita Medical Limited issued the following letter to shareholders:
- Business Wire•24 days ago
U.S. FDA Approves Increased Compassionate Use Patient Cases and Sites for ReCell® in Life-Threatening Injuries
The U.S. Food and Drug Administration has approved a further increase in the number of patients who can be treated in the United States with the ReCell® regenerative medical device under a compassionate use protocol, Avita Medical Ltd.
- Business Wire•last month
Avita Medical Limited , a regenerative medicine company focused on the treatment of wounds and skin defects, today announced that Adam Kelliher, Avita’s Chief Executive Officer will present at the 16th Annual Needham Healthcare Conference on 4 April 2017.
AVH.AX : Summary for AVITA MED FPO - Yahoo Finance
Avita Medical Limited (AVH.AX)
ASX - ASX Delayed Price. Currency in AUD
Add to watchlist
|Day's Range||0.09 - 0.09|
|52 Week Range||0.09 - 0.14|
|PE Ratio (TTM)||-6.00|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|